At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 627 enrolled
Drug / intervention
BMS-986205 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986205, Nivolumab, and 1 other intervention for Advanced Cancer and 2 related conditions. Completed, enrolled 627 participants across 47 sites in 11 countries.
Detailed Summary
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer, Melanoma, Non-Small Cell Lung Cancer
CountriesAustralia, Canada, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartApr 2016
Primary CompletionOct 2021
TodayJul 2026
First PostedJan 20, 2016
Enrollment StartApr 14, 2016
Primary CompletionOct 26, 2021
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 10.5 years ago
Interventions
BMS-986205drug
Nivolumabdrug
Ipilimumabdrug